Thermo Fisher Scientific Total Operating Expenses increased by 5.7% to $9.14B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.7%, from $8.65B to $9.14B. Over 3 years (FY 2021 to FY 2024), Total Operating Expenses shows an upward trend with a 6.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Investors compare this to revenue to assess the 'operating leverage' of a business model.
total_operating_expenses| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.11B | $7.05B | $8.16B | $9.00B | $8.97B | $8.97B | $9.59B | $9.15B | $9.11B | $8.71B | $9.03B | $8.68B | $8.72B | $8.76B | $9.38B | $8.65B | $9.14B |
| QoQ Change | — | -0.8% | +15.8% | +10.2% | -0.3% | -0.0% | +6.9% | -4.6% | -0.4% | -4.4% | +3.7% | -3.9% | +0.5% | +0.4% | +7.1% | -7.8% | +5.7% |
| YoY Change | — | — | — | — | +26.1% | +27.2% | +17.5% | +1.7% | +1.6% | -2.9% | -5.8% | -5.1% | -4.2% | +0.6% | +3.8% | -0.4% | +5.7% |